Past Cases of EBV-LPD in Stem Cell Transplant Patients at Indiana University
| Treatment . | Total Patients . | Complete Remission (%) . | Disease Progression (%) . | GVHD (%) . | Patients Surviving (%) . |
|---|---|---|---|---|---|
| Observation | 6 | 0 (0) | 6 (100) | 0 (0) | 0 (0) |
| Interferon, IVIg4-150 | 2 | 0 (0) | 2 (100) | 0 (0) | 0 (0) |
| Chemotherapy | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Excision | 1 | 1 (100) | 0 (0) | 0 (0) | 1 (100) |
| Donor leukocytes | 13 | 4 (31) | 9 (69)4-151 | 4 (31) | 2 (15)‡ |
| Treatment . | Total Patients . | Complete Remission (%) . | Disease Progression (%) . | GVHD (%) . | Patients Surviving (%) . |
|---|---|---|---|---|---|
| Observation | 6 | 0 (0) | 6 (100) | 0 (0) | 0 (0) |
| Interferon, IVIg4-150 | 2 | 0 (0) | 2 (100) | 0 (0) | 0 (0) |
| Chemotherapy | 1 | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Excision | 1 | 1 (100) | 0 (0) | 0 (0) | 1 (100) |
| Donor leukocytes | 13 | 4 (31) | 9 (69)4-151 | 4 (31) | 2 (15)‡ |
Treatment outcomes in 23 stem cell transplant patients with EBV-LPD at Indiana University.
Intravenous immunoglobulin.
Five of these nine patients died 2 to 10 days after receiving donor leukocytes and had advanced EBV-LPD at the time of diagnosis and treatment.
One of these patients received EBV-specific CTL and one patient unprimed donor leukocytes.